MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis

[1]  S. Lippman,et al.  Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. , 2017, Cancer research.

[2]  R. Kurzrock,et al.  Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma , 2017, Clinical Cancer Research.

[3]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[4]  Dorota Kwapisz,et al.  The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? , 2017, Annals of translational medicine.

[5]  F. Saad,et al.  Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Powles,et al.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[7]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[8]  O. Harismendy,et al.  Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients , 2016, Clinical Cancer Research.

[9]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[10]  F. Rojo,et al.  Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer , 2015, Journal of Translational Medicine.

[11]  Richard B. Schwab,et al.  Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay , 2016, Oncotarget.

[12]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[13]  K. Hess,et al.  MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. , 2015, Clinical genitourinary cancer.

[14]  K. Hess,et al.  Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. , 2014, Clinical breast cancer.

[15]  K. Hess,et al.  Personalized Medicine and Imaging Analysis of 1 , 115 Patients Tested for MET Ampli fi cation and Therapy Response in the MD Anderson Phase I Clinic , 2014 .

[16]  T. Kamoto,et al.  Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis , 2014, Human Cell.

[17]  K. Nishio,et al.  Targeting MET Amplification as a New Oncogenic Driver , 2014, Cancers.

[18]  A. Iafrate,et al.  Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). , 2014 .

[19]  Gary Box,et al.  Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. , 2014, Journal of the National Cancer Institute.

[20]  K. Hess,et al.  MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit , 2014, Oncotarget.

[21]  V. Servois,et al.  Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma , 2014, International journal of cancer.

[22]  T. Choueiri,et al.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. , 2014, European urology.

[23]  K. Hess,et al.  MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors , 2013, Oncoscience.

[24]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[25]  L. Mariani,et al.  MET Gain in Diffuse Astrocytomas is Associated with Poorer Outcome , 2013, Brain pathology.

[26]  M. Ratain,et al.  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[28]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[29]  N. Fausto.  Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804 , 1991 .

[30]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[31]  M. Braun,et al.  Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Cooper,et al.  Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.